Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M G SteffensE Oosterwijk

Abstract

Pharmacokinetics, biodistribution, immunogenicity, and imaging characteristics of iodine 131 (131I)-labeled chimeric monoclonal antibody (mAb) G250 (cG250) were studied in patients with renal cell carcinoma (RCC) to determine the therapeutic potential of this antibody. Sixteen patients with RCC received a single intravenous (IV) infusion of 6 mCi 131I-labeled cG250. Five protein dose levels were investigated (2 to 50 mg). Planar scintigraphic images were acquired, and normal tissue biopsies and tumor samples were obtained of surgery (7 days postinjection). The immunogenicity of cG250 was investigated using a sandwich enzyme-linked immunosorbent assay (ELISA) and dosimetric analysis was performed. In all patients with antigen-positive tumors (n = 13), the primary tumors and all known metastases were clearly visualized. Overall uptake, expressed as the percentage of the injected dose (%ID), in the primary tumors ranged from 2.4 to 9.0. Focally, 131I-cG250 uptake as high as 0.52% ID/g was observed. However, intratumoral uptake was highly heterogeneous. 131I-cG250 uptake in nontumorous tissues remained low. Dosimetric analysis showed that up to .48 Gy/mCi was guided to the primary tumors. Selected "hot areas" within these tumors re...Continue Reading

Citations

Jan 23, 1999·The Journal of Urology·R A Figlin
Apr 1, 2000·Laboratory Investigation; a Journal of Technical Methods and Pathology·V T BlokA Gorter
Dec 18, 2001·International Journal of Cancer. Journal International Du Cancer·G PavlinkovaS K Batra
Apr 20, 2007·BJU International·Egbert OosterwijkNeil H Bander
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley C LeibovichEugene D Kwon
Jun 22, 2016·Nature Reviews. Urology·Maria I CarloRobert J Motzer
Nov 26, 1999·British Journal of Cancer·H UemuraE Oosterwijk
Jun 7, 2003·Scandinavian Journal of Immunology·V T BlokA Gorter
Jul 13, 2006·European Journal of Nuclear Medicine and Molecular Imaging·Julliëtte E M van EerdOtto C Boerman
Sep 27, 2005·The Journal of Pharmacology and Experimental Therapeutics·Chiaki EbiharaYoshiteru Watanabe
Mar 8, 2005·Cancer Immunology, Immunotherapy : CII·Sonja OffnerBirgit Kohleisen
Feb 2, 2008·World Journal of Urology·Egbert OosterwijkPeter F A Mulders
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Andrew M ScottLloyd J Old
Jul 27, 2005·BJU International·John T LeppertArie S Belldegrun
Apr 24, 2008·BJU International·Egbert Oosterwijk
Jan 12, 2010·Annual Review of Medicine·W Marston LinehanRamaprasad Srinivasan
Sep 1, 2007·Expert Opinion on Medical Diagnostics·Guorong LiJacques Tostain
Aug 4, 2015·Future Oncology·Fouad AounThierry Roumeguère
Dec 12, 2001·BJU International·Z KirkaliM U Mungan
Feb 19, 2005·Current Oncology Reports·John S LamRobert A Figlin
Sep 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adrienne H BrouwersWim J G Oyen
Aug 22, 2006·Cancer Biotherapy & Radiopharmaceuticals·Baudewijn W HendrickxWim J G Oyen
Apr 23, 2009·International Journal of Cancer. Journal International Du Cancer·Stefan BauerChristoph Renner
May 29, 2008·Cancer Metastasis Reviews·Rodolfo PeriniMark A Rosen
Feb 13, 2010·Current Opinion in Oncology·Kirsten Bouchelouche, Jacek Capala
Jan 13, 2006·Cancer Metastasis Reviews·Manuel J KoppeOtto C Boerman
Jun 14, 2013·International Journal of Molecular Sciences·Jeannette C Oosterwijk-WakkaEgbert Oosterwijk
May 24, 2013·Cancer Biotherapy & Radiopharmaceuticals·Alexander B StillebroerOtto C Boerman
Jun 27, 2002·Current Urology Reports·B J GitlitzA S Belldegrun
Jun 10, 2004·Cancer Biotherapy & Radiopharmaceuticals·Adrienne BrouwersOtto Boerman
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S K ChiaA L Harris
Jul 5, 2005·Expert Opinion on Investigational Drugs·S MukerjeeM C Glassy
Jun 1, 2009·Therapeutic Advances in Urology·Eamonn E BahnsonRobert R Bahnson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
E OosterwijkG J Fleuren
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Adrienne H BrouwersWim J G Oyen
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Adrienne H BrouwersOtto C Boerman
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
M G SteffensOtto C Boerman
© 2021 Meta ULC. All rights reserved